跳转至内容
Merck
CN

SML2091

Dalcetrapib

≥97% (HPLC)

别名:

JTT-705, RO-4607381, S-[2-[[1-(2-ethylbutyl)cyclohexane]carbonylamino]phenyl]-2-methylpropanethioate

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C23H35NO2S
化学文摘社编号:
分子量:
389.59
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥97% (HPLC)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


assay

≥97% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

CC(C)C(SC1=CC=CC=C1NC(C2(CCCCC2)CC(CC)CC)=O)=O

InChI

1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)

InChI key

YZQLWPMZQVHJED-UHFFFAOYSA-N

Biochem/physiol Actions

Cholesteryl ester transfer protein (CETP) inhibitor; increases serum levels of HDL-cholesterol
Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. It increases HDL levels, but showed variable results on clinical outcomes. Clinical outcomes, effects on C-reactive protein and cholesterol efflux have been found to be genotype-dependent, influenced by correlated polymorphisms in the ADCY9 (adenylate cyclase type 9) gene. Positive results were obtained with AA genotype of ADCY9 gene whereas the GG genotype showed negative results and the AG genotype was neutral.


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Jean-Claude Tardif et al.
Arteriosclerosis, thrombosis, and vascular biology, 37(3), 396-400 (2017-01-28)
High-density lipoproteins are involved in reverse cholesterol transport and possess anti-inflammatory and antioxidative properties. Paradoxically, CETP (cholesteryl ester transfer protein) inhibitors have been shown to increase inflammation as revealed by a raised plasma level of high-sensitivity C-reactive protein. CETP inhibitors
Marie-Jeanne Bertrand et al.
Expert opinion on emerging drugs, 22(1), 1-26 (2016-12-09)
Cardiovascular (CV) atherosclerotic disease remains the leading cause of morbidity and mortality worldwide, despite the advances in contemporary therapies. Inflammation is an important process in atherosclerosis, leading to plaque rupture and acute coronary syndrome. Although statin therapy has substantially reduced



全球贸易项目编号

货号GTIN
SML2091-25MG04061835502400
SML2091-5MG04061835502417